96 related articles for article (PubMed ID: 37659727)
1. A tumor-infiltrating immune cells-related pseudogenes signature based on machine-learning predicts outcomes and immunotherapy responses in ovarian cancer.
Zhang Y; Guo M; Wang L; Weng S; Xu H; Ren Y; Liu L; Guo C; Cheng Q; Luo P; Zhang J; Han X
Cell Signal; 2023 Nov; 111():110879. PubMed ID: 37659727
[TBL] [Abstract][Full Text] [Related]
2. Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer.
Huan Q; Cheng S; Ma HF; Zhao M; Chen Y; Yuan X
J Cell Mol Med; 2024 Jan; 28(1):e18021. PubMed ID: 37994489
[TBL] [Abstract][Full Text] [Related]
3. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
4. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
[TBL] [Abstract][Full Text] [Related]
5. Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma.
Zhang N; Zhang H; Wu W; Zhou R; Li S; Wang Z; Dai Z; Zhang L; Liu F; Liu Z; Zhang J; Luo P; Liu Z; Cheng Q
Theranostics; 2022; 12(13):5931-5948. PubMed ID: 35966587
[No Abstract] [Full Text] [Related]
6. Application of Machine Learning in Developing a Novelty Five-Pseudogene Signature to Predict Prognosis of Head and Neck Squamous Cell Carcinoma: A New Aspect of "Junk Genes" in Biomedical Practice.
Xing L; Zhang X; Guo M; Zhang X; Liu F
DNA Cell Biol; 2020 Apr; 39(4):709-723. PubMed ID: 32045271
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
8. A Four-Pseudogene Classifier Identified by Machine Learning Serves as a Novel Prognostic Marker for Survival of Osteosarcoma.
Liu F; Xing L; Zhang X; Zhang X
Genes (Basel); 2019 May; 10(6):. PubMed ID: 31146489
[TBL] [Abstract][Full Text] [Related]
9. Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
Chen H; Yang W; Ji Z
Front Immunol; 2023; 14():1171420. PubMed ID: 37063886
[TBL] [Abstract][Full Text] [Related]
10. Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma.
Zhang H; Zhang N; Wu W; Zhou R; Li S; Wang Z; Dai Z; Zhang L; Liu Z; Zhang J; Luo P; Liu Z; Cheng Q
Brief Bioinform; 2022 Nov; 23(6):. PubMed ID: 36136350
[TBL] [Abstract][Full Text] [Related]
11. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
12. An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients.
Tang S; Zhuge Y
Biomed Eng Online; 2021 Jun; 20(1):64. PubMed ID: 34193185
[TBL] [Abstract][Full Text] [Related]
13. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
Front Immunol; 2021; 12():691811. PubMed ID: 34489938
[TBL] [Abstract][Full Text] [Related]
14. Multi-omics identification of an immunogenic cell death-related signature for clear cell renal cell carcinoma in the context of 3P medicine and based on a 101-combination machine learning computational framework.
Liu J; Shi Y; Zhang Y
EPMA J; 2023 Jun; 14(2):275-305. PubMed ID: 37275552
[TBL] [Abstract][Full Text] [Related]
15. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer.
Zhou M; Zhang Z; Bao S; Hou P; Yan C; Su J; Sun J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32382761
[TBL] [Abstract][Full Text] [Related]
16. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
17. Construction of a Matrix Cancer-Associated Fibroblast Signature Gene-Based Risk Prognostic Signature for Directing Immunotherapy in Patients with Breast Cancer Using Single-Cell Analysis and Machine Learning.
Huang B; Chen Q; Ye Z; Zeng L; Huang C; Xie Y; Zhang R; Shen H
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685980
[TBL] [Abstract][Full Text] [Related]
18. Identification of a 15-pseudogene based prognostic signature for predicting survival and antitumor immune response in breast cancer.
Tan L; He X; Shen G
Aging (Albany NY); 2020 Dec; 13(10):14499-14521. PubMed ID: 33378744
[TBL] [Abstract][Full Text] [Related]
19. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
20. Machine Learning-Devised Immune-Related lncRNA Signature Panel Predicts the Prognosis and Immune Landscape in Breast Cancer Novel IRLP Signature in BRCA.
Zhu JY; Lyu AQ; Wang ZT; Chan WY; Qin T; Miu KK; Yao HR
J Immunol Res; 2022; 2022():3704798. PubMed ID: 36033386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
